Concepts for the implementation of a technological platform for the production of specific antidotes for CBRN medical protection

Abstract

"Abstract: All large armies (EU and/or NATO) have pharmaceutical production facilities to provide the necessary antidotes for the troops and the population: The French Army Medical Directorate produces many military-specific pharmaceutical products in its own laboratory, the Turkish Army owns its own medicines factory, including CBRN antidotes, the US Army, in addition to a sustained drug purchase program in the pharmaceutical industry has launched a new concept: Pharmacy on demand. Providing the armed forces with antidotes is a necessity, the concept for their endowement in this sense can be based on imports (sometimes impossible to achieve) or on the national development of a specialized production structure. The design or construction of a specific production capacity for antidotes can be accomplished on multiple variants, with a complexity proportional to the identified need. The total costs are high, but the objective and implementation of effective antidote supply mechanisms is a security guarantee for the armed forces and the civilian population (through commercialization to allied forces), given the risks of terrorist threats and hybrid warfare. Keywords: medical protection, antidote, production, technological platform, medical countermeasures, pharmaceutical technique, orphan drug production "

Identification and Analysis of Parameters and Global Experiences of Hospital Preparedness Against Chemical, Biological, Radiological and Nuclear Disasters: A Scoping Review

“…Pharmaceutical laboratories required to produce antidotes include drug control and quality assurance laboratory, chemical synthesis of pharmaceutical materials laboratory, microbiology laboratory for analysis and administration of pharmacological microbiology tests, medical and biosafety laboratories, laboratory of analyzing and conducting in-vivo experiments on animals, and R&D centers to apply their findings in the field of pharmacy. The technological platform to produce antidotes for CBRN medical protection can be developed at three scales, minimum, medium or maximum, depending on the existing needs and facilities (46). In the study of Treat et al, there was only a single specialized pharmaceutical center for the victims of WMDs (11).…”